Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Ejaculation-Preserving Versus Conventional Dual Wavelength Diode Laser Vaporization of the Prostate (EP-TUVP)

16. August 2026 aktualisiert von: ALI KAMAL M. SAMI

Ejaculation-Preserving Versus Conventional Dual-Wavelength Diode Laser Vaporization of the Prostate: A Randomized Comparative Study With 12-Month Follow up

Surgery to relieve urinary blockage caused by an enlarged prostate works well, but most men lose antegrade ejaculation afterwards, because semen passes backwards into the bladder instead of forwards. For sexually active men this is an important concern and a common reason for delaying or refusing surgery.

This study compared two ways of performing the same operation, laser vaporization of the prostate using a dual-wavelength diode laser. In the conventional technique, prostate tissue is removed from the bladder neck all the way to the verumontanum. In the ejaculation-preserving technique, the surgeon deliberately leaves a 10 mm rim of tissue at the bladder neck untouched, and another 10 mm of tissue just before the verumontanum untouched, while removing the blocking tissue in between. Everything else about the operation, including the laser settings, was the same.

Men were assigned to one of the two techniques by a computer-generated random sequence. They were assessed before surgery and again at 7 to 14 days, 1 month, 3 months, 6 months and 12 months after surgery.

The main question was how many men still had antegrade ejaculation 3 months after surgery. The study also compared urinary symptoms, urine flow rate, residual urine volume, prostate size, erectile function, complications and patient satisfaction, to find out whether preserving ejaculation costs anything in terms of relieving the urinary blockage.

Studienübersicht

Status

Abgeschlossen

Bedingungen

Intervention / Behandlung

Detaillierte Beschreibung

BACKGROUND

Loss of antegrade ejaculation follows conventional transurethral resection or vaporization of the prostate in the majority of men. Two anatomical regions are considered central to this: the internal urethral sphincter at the bladder neck, which prevents retrograde passage of semen, and the paracollicular and supracollicular tissue around the verumontanum, which contributes to the emission phase. Techniques preserving one or both regions have been described across several endoscopic platforms, but evidence specific to the dual-wavelength diode laser is limited and follow-up in previous work has been short.

OBJECTIVE

To determine whether an ejaculation-preserving technique of dual-wavelength diode laser vaporization of the prostate preserves antegrade ejaculation without compromising relief of bladder outlet obstruction, and whether any benefit is durable to 12 months.

DESIGN

Prospective, randomized, single-centre comparative study conducted at the Department of Urology, Royal Hospital, Sulaymaniyah, Kurdistan Region, Iraq. Allocation followed a computer-generated random sequence, with assignments concealed in sequentially numbered opaque sealed envelopes opened after consent. Participants were not informed of their allocation. The operating surgeon was necessarily aware of allocation.

INTERVENTION

All procedures were performed by a single surgeon under spinal or general anaesthesia, using a 22 Fr continuous-flow laser cystoscope sheath with normal saline irrigation. Energy was delivered by a Ceralas dual-wavelength diode laser system (biolitec biomedical technology GmbH, Jena, Germany) emitting simultaneously at 980 nm and 1470 nm, through a bare-tip fibre in continuous-wave mode at a total power of 140 W. Laser wavelength, fibre type, emission mode and power setting were identical in both arms.

Conventional arm: vaporization proceeded from the bladder neck to the verumontanum in the standard fashion, including tissue at the bladder neck and immediately proximal to the verumontanum, until a wide channel was created.

Ejaculation-preserving arm: no vaporization was performed within 10 mm distal to the bladder neck, and no vaporization was performed within 10 mm proximal to the verumontanum. Between these two margins, the lateral lobes, median lobe and anterior tissue were vaporized to the same endpoint as in the conventional arm. Adherence to both margins was recorded prospectively in every case.

ASSESSMENTS

Participants were assessed at baseline and at day 7 to 14, 1 month, 3 months, 6 months and 12 months. Symptoms were quantified with the International Prostate Symptom Score and its quality-of-life item, and erectile function with the five-item International Index of Erectile Function. Uroflowmetry was accepted only with a voided volume of at least 150 mL. Post-void residual volume and prostate volume were measured by transabdominal ultrasound. Ejaculatory status was recorded as a binary patient-reported outcome: presence or absence of any antegrade ejaculate during sexual activity since the preceding visit. Complications were graded using the Clavien-Dindo classification.

ANALYSIS

Continuous variables were compared between arms with the Mann-Whitney U test and within arms against baseline with the Wilcoxon signed-rank test. Proportions were compared with the two-sided Fisher exact test, with risk differences reported using Newcombe hybrid-score 95 percent confidence intervals. No imputation was performed. Analysis was restricted to participants with complete records at every scheduled visit.

NOTE ON REGISTRATION

This trial was registered retrospectively. The protocol, including the primary endpoint, the secondary endpoints and the two 10 mm technical margins, was submitted to and registered by the Scientific Committee of the Department of Clinical Sciences, College of Medicine, University of Sulaimani (number 28, 25 February 2025) and approved by the Ethics Committee of the same institution (number 62, 2 March 2025). Public registry registration was not undertaken before enrolment because the requirement was not appreciated at the time. No outcome measures, eligibility criteria or analysis definitions were altered after the study began.

Studientyp

Interventionell

Einschreibung (Tatsächlich)

119

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

    • Kurdistan
      • Sulaymaniyah, Kurdistan, Irak, 46001
        • Royal Hospital, Department of Urology

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

  • Erwachsene
  • Älterer Erwachsener

Akzeptiert gesunde Freiwillige

Nein

Beschreibung

Inclusion Criteria:

  • Male, aged 50 years or older
  • Lower urinary tract symptoms attributable to benign prostatic obstruction
  • International Prostate Symptom Score of 16 or more
  • Maximum urinary flow rate below 15 mL/s on a uroflowmetry study with a voided volume of at least 150 mL
  • Prostate volume between 30 and 150 cc on transabdominal ultrasound
  • Indication for surgery after failure of or intolerance to medical therapy
  • Preserved antegrade ejaculation at baseline
  • Currently sexually active
  • Willing and able to attend all scheduled follow-up visits
  • Written informed consent, including specific consent to discussion and recording of ejaculatory function

Exclusion Criteria:

  • Suspected or confirmed prostate cancer
  • Prostate-specific antigen above the age-specific reference range without a benign explanation
  • Neurogenic bladder
  • Urethral stricture
  • Bladder stones
  • Previous prostatic or urethral surgery
  • Absent antegrade ejaculation at baseline
  • Erectile dysfunction sufficient to preclude sexual activity

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Single

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Aktiver Komparator: conventional tuvp
Conventional dual-wavelength diode laser vaporization of the prostate. Vaporization proceeded from the bladder neck to the verumontanum in the standard fashion, with removal of obstructing adenoma including the tissue at the bladder neck and immediately proximal to the verumontanum, until a wide channel was created
Transurethral vaporization of the prostate using a Ceralas dual-wavelength diode laser (biolitec biomedical technology GmbH, Jena, Germany) emitting simultaneously at 980 nm and 1470 nm, bare-tip fibre, continuous wave, total power 140 W, delivered through a 22 Fr continuous-flow laser cystoscope sheath with normal saline irrigation, under spinal or general anaesthesia. Adenoma was vaporized from the bladder neck to the verumontanum without preservation margins.
Experimental: Ejaculation-Preserving TUVP (EP-TUVP)
Ejaculation-preserving dual-wavelength diode laser vaporization of the prostate. No vaporization was performed within 10 mm distal to the bladder neck, preserving the circular muscle fibres of the internal sphincter, and no vaporization was performed within 10 mm proximal to the verumontanum, preserving the paracollicular and supracollicular tissue. Between these two margins, the lateral lobes, median lobe and anterior tissue were vaporized to the same endpoint as in the conventional arm. Laser settings were identical to the comparator arm.
Identical equipment, laser settings and anaesthesia to the comparator intervention, with two preservation margins: no vaporization within 10 mm distal to the bladder neck and none within 10 mm proximal to the verumontanum. Adequacy of the mid-prostatic channel was confirmed endoscopically at the end of the procedure. Adherence to both margins was recorded prospectively for every case.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Preservation of antegrade ejaculation
Zeitfenster: 3 months after surgery
Proportion of participants reporting the presence of any antegrade ejaculate during sexual activity since the preceding visit. Recorded as a binary patient-reported outcome (present or absent). All participants had antegrade ejaculation at baseline as an eligibility requirement.
3 months after surgery

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Durability of integrate ejaculation preservation
Zeitfenster: 6 and 12 months after surgery
Proportion of participants reporting presence of any antegrade ejaculate, assessed as for the primary outcome, to test whether any benefit is sustained over time.
6 and 12 months after surgery
Change in international prostate symptom score IPSS
Zeitfenster: Baseline, 3, 6, and 12 months after surgery
IPSS total score, range 0 to 35, where higher scores indicate more severe lower urinary tract symptoms. Change from baseline is reported.
Baseline, 3, 6, and 12 months after surgery
Change in IPSS quality of life score
Zeitfenster: Baseline, 3, 6, and 12 months after surgery
Single-item IPSS quality-of-life question, range 0 to 6, where higher scores indicate worse bother from urinary symptoms.
Baseline, 3, 6, and 12 months after surgery
Change in maximum urinary flow rate (Qmax)
Zeitfenster: Baseline, 3, 6, and 12 months after surgery
Maximum flow rate in mL/s measured by uroflowmetry, accepted only when voided volume was at least 150 mL. Higher values indicate better flow.
Baseline, 3, 6, and 12 months after surgery
Change in post-void residual urine volume
Zeitfenster: Baseline, 3, 6, and 12 months after surgery
Post-void residual volume in mL measured by transabdominal ultrasound. Lower values indicate more complete bladder emptying.
Baseline, 3, 6, and 12 months after surgery
Change in prostate volume
Zeitfenster: Baseline, 3, 6, and 12 months after surgery
prostate volume in cc measured by transabdominal ultrasound, using the prolate, elipsoid formula with percentage reduction from baseline calculated
Baseline, 3, 6, and 12 months after surgery
Change in erectile function (IIEF-5)
Zeitfenster: Baseline, 3, 6, and 12 months after surgery
Five-item International Index of Erectile Function, range 5 to 25, where higher scores indicate better erectile function. Assessed as a control variable to distinguish ejaculatory from erectile outcomes. Face like, three, six, and 12 months after
Baseline, 3, 6, and 12 months after surgery
Complications graded by Clavien-Dindo classification
Zeitfenster: From surgery to 12 months after surgery
Clavien-Dindo grade recorded per participant, from grade I (any deviation from normal course) to grade V (death), including in-hospital and all follow-up intervals.
From surgery to 12 months after surgery
Patient global satisfaction
Zeitfenster: 3, 6, and 12 months after surgery
Patient-reported global satisfaction with the outcome of surgery on a 5-point scale, where 1 indicates very dissatisfied and 5 indicates very satisfied.
3, 6, and 12 months after surgery
Trifecta outcome
Zeitfenster: 12 months after surgery
Composite endpoint requiring all three of: IPSS below 8, complete pad independence, and preserved antegrade ejaculation.
12 months after surgery
Operative time, catheterization time and hospital stay
Zeitfenster: Day of surgery to hospital discharge, up to seven days
Operative time in minutes measured from insertion to withdrawal of the cystoscope, duration of postoperative catheterisation in hours, and length of hospital stay in hours.
Day of surgery to hospital discharge, up to seven days
Early post operative dysuria
Zeitfenster: Day 7 to 14 and 1month after surgery
Dysuria severity on a visual analogue scale from 0 to 10, where higher scores indicate more severe dysuria, together with the duration of dysuria in days.
Day 7 to 14 and 1month after surgery
Re-treatment for benign prostatic obstruction
Zeitfenster: Up to 12 months after surgery
Proportion of participants requiring any further surgical intervention for benign prostatic obstruction.
Up to 12 months after surgery

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Publikationen und hilfreiche Links

Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

5. Oktober 2024

Primärer Abschluss (Tatsächlich)

27. Oktober 2025

Studienabschluss (Tatsächlich)

20. Juli 2026

Studienanmeldedaten

Zuerst eingereicht

16. August 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

16. August 2026

Zuerst gepostet (Tatsächlich)

20. August 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

20. August 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

16. August 2026

Zuletzt verifiziert

1. August 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Andere Studien-ID-Nummern

  • UOS-COM-62-2024
  • UOS-COM-ETHICS-62 (Andere Kennung: Ethics Committee, College of Medicine, University of Sulaimani)
  • UOS-CSD-REG-28 (Andere Kennung: Clinical Sciences Department Scientific Committee, University of Sulaimani)

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

JA

Beschreibung des IPD-Plans

De-identified individual participant data underlying the published results, including baseline characteristics, operative details, and all follow-up outcome measurements, will be made available to qualified investigators.

IPD-Sharing-Zeitrahmen

Beginning 6 months after publication of the primary results and ending 5 years thereafter.

IPD-Sharing-Zugriffskriterien

Requests should be directed to the principal investigator and must include a methodologically sound proposal and a stated analysis objective. Data will be released after review of the proposal and completion of a data access agreement.

Art der unterstützenden IPD-Freigabeinformationen

  • STUDIENPROTOKOLL
  • SAFT
  • ICF

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .